ArticleDiscover oncology2026
Anlotinib inhibits esophageal cancer malignancy by ameliorating the immune microenvironment.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Esophageal cancer (EC) is a global health challenge with limited treatment and low efficacy. The role of vascular endothelial growth factor receptor 2 (VEGFR2) in EC has attracted significant attention. In this study, we found that anlotinib, an oral VEGFR2 inhibitor, exhibited a strong inhibitory effect on EC in vitro and in vivo. Moreover, VEGFR2 expression was positively correlated with infiltration levels of macrophages and dendritic cells (DCs) via comprehensive analysis and molecular experiment. Together, we evaluated the correlations between VEGFR2 expression and immune infiltration and explored the role of anlotinib on EC, providing a potential strategy for the intervention of EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.